Skip to search formSkip to main contentSkip to account menu

AZD3514

Known as: Androgen Receptor Downregulator AZD3514, SARD AZD3514 
An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
La voie de signalisation du recepteur des androgenes (RA) reste une cible therapeutique privilegiee dans les cancers de la… 
2016
2016
First‐in‐human (FIH) studies with AZD3514, a selective androgen receptor (AR) down‐regulator, showed decreases of >30% in the… 
2016
2016
Purpose: To describe the pharmacokinetics (PK) and pharmacodynamics (PD) of AZD3514 and how the design of the first-time-in-human… 
2016
2016
Introduction: Olaparib, a PARP inhibitor has produced promising antitumor efficacy in patients with BRCA mutation. However… 
2014
2014
AZD3514 inhibits and down regulates the androgen receptor (AR) and has undergone clinical trials in prostate cancer. To provide… 
2013
2013
4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent… 
2012
2012
The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found…